Ipsen announced its acquisition of portfolio company Kartos Therapeutics to expand its hemato-oncology pipeline.
Kartos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, targeted therapies to improve the lives of cancer patients
Kartos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, targeted therapies to improve the lives of cancer patients. Their lead investigational drug, navtemadlin (KRT-232), is a potent and selective oral MDM2 inhibitor designed to reactivate the tumor-suppressing function of p53 by inhibiting the MDM2-p53 interaction.